BIO-SWITCH study: Biosimilar of Infliximab Options, Strengths and Weaknesses of Infliximab Treatment CHange

Trial Profile

BIO-SWITCH study: Biosimilar of Infliximab Options, Strengths and Weaknesses of Infliximab Treatment CHange

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms BIO-SWITCH
  • Most Recent Events

    • 18 Oct 2017 Status changed from recruiting to active, no longer recruiting as per the results published in the Arthritis and Rheumatology
    • 18 Oct 2017 Results published in the Arthritis and Rheumatology
    • 24 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top